TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23751742

Group type: EXPERIMENTAL
Intervention: GRP78 positive cells in ovarian serous adenocarcinoma
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: mRNA expressions of GRP78
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Protein expressions of GRP78
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: GRP78 expression
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: GRP78 mRNA and protein expression
Number of subjects: 126
Study: 20834185

Group type: EXPERIMENTAL
Intervention: Low-dose Erythropoietin (6,000 IU during PCI, 24h and 48h)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 35
Study: 19098656

Group type: EXPERIMENTAL
Intervention: Heated humidified CO2
Number of subjects: 565

Group type: COMPARATOR
Intervention: Standard dry CO2
Number of subjects: 565
Study: 15803314

Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg/day; n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enalapril (5 mg/day; n = 20)
Number of subjects: 40
Study: 12464839

Group type: EXPERIMENTAL
Intervention: Pain education program
Number of subjects: 37
Study: 10329810

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 25 micrograms to 500 micrograms, twice daily
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1461
Study: 7851579

Group type: EXPERIMENTAL
Intervention: Oral 17 beta-E2 with high dose of CPA
Number of subjects: 65

Group type: COMPARATOR
Intervention: Transdermal 17 beta-E2 with high dose of CPA
Number of subjects: 65
Study: 2046254

Group type: EXPERIMENTAL
Intervention: Ethacizine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Bonnecor
Number of subjects: 77
Study: 7015912

Group type: EXPERIMENTAL
Intervention: Budesonide (topical corticosteroid)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31848231

Group type: EXPERIMENTAL
Intervention: Immediate disease-modifying therapy (DMT)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Delayed disease-modifying therapy (DMT)
Number of subjects: 328
Study: 31113794

Group type: EXPERIMENTAL
Intervention: ixekizumab
Number of subjects: 402

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 402
Study: 28640124

Group type: EXPERIMENTAL
Intervention: Anesthesia machine: Excel, Avance, Cato, Primus with low-flow anesthesia (0.5, 1, and 4 L/min)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Anesthesia machine: Cato and Primus with fresh gas flow of 4 L/min
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: All anesthesia machines with low-flow anesthesia
Number of subjects: 99
Study: 25888851

Group type: EXPERIMENTAL
Intervention: SrRan 2 g/day
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 24007540

Group type: EXPERIMENTAL
Intervention: Birth Preparation Program (BPP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Routine prenatal care (Control)
Number of subjects: 21
Study: 21309961

Group type: EXPERIMENTAL
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12 mg/day rivastigmine capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4.6 mg/24 h rivastigmine patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18704426

Group type: EXPERIMENTAL
Intervention: rhTNFR:Fc (25 mg, subcutaneous injection, twice weekly)
Number of subjects: 238
Study: 16996230

Group type: EXPERIMENTAL
Intervention: ST brand switching with controlled ST topography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ST brand switching with ad libitum ST use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 15528877

Group type: EXPERIMENTAL
Intervention: Granulocyte and monocyte adsorption apheresis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 20
Study: 11057435

Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg
Number of subjects: 411

Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 411

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 411
Study: 9309627

Group type: EXPERIMENTAL
Intervention: Cross-training (C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Endurance-only (E)
Number of subjects: 16
Study: 8340716

Group type: EXPERIMENTAL
Intervention: Standardized force of 2 or 3 kg applied with a 1 cm2 rubber-tipped pressure algometer
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham test
Number of subjects: 42
Study: 3529677

Group type: EXPERIMENTAL
Intervention: Vitamin E (daily dose 400 I.E. d‐alpha‐tocopherylacetate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vitamin E and Placebo
Number of subjects: 50
Study: 31026298

Group type: EXPERIMENTAL
Intervention: Social and preventive medicine consultation (intervention group)
Number of subjects: 976

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 976
Study: 28760534

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized Japanese cedar pollen extract
Number of subjects: 482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study: 26991399

Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg twice daily (b.d.)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: esomeprazole 20 mg b.d.
Number of subjects: 28

Group type: COMPARATOR
Intervention: esomeprazole 20 mg daily
Number of subjects: 28
Study: 25419402

Group type: EXPERIMENTAL
Intervention: Loaded deep inhale training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular aerobics (jogging)
Number of subjects: 30
Study: 22796949

Group type: EXPERIMENTAL
Intervention: Exposure to palatable food
Number of subjects: 0
Study: 20096622

Group type: EXPERIMENTAL
Intervention: Liposomal spray
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline spray (control)
Number of subjects: 22
Study: 18671464

Group type: EXPERIMENTAL
Intervention: Various treatment options including surgery, radiotherapy, and systemic chemotherapy.
Number of subjects: 0
Study: 15972867

Group type: EXPERIMENTAL
Intervention: Standard 24-week regimen of peginterferon alfa-2b at a dose of 1.0 mug per kilogram weekly plus ribavirin at a dose of 1000 mg or 1200 mg daily.
Number of subjects: 283

Group type: COMPARATOR
Intervention: Variable 12 or 24-week regimen depending on HCV RNA results at week 4.
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Standard 24-week regimen
Number of subjects: 283

Group type: COMPARATOR
Intervention: Variable 12 or 24-week regimen
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Variable 12-week regimen
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Overall response for genotype 2
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Overall response for genotype 3
Number of subjects: 283
Study: 12571845

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 40 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 68
Study: 10929792

Group type: EXPERIMENTAL
Intervention: GAD group
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: PD group
Number of subjects: 117

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 117
Study: 8765493

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) treatment, 30 mg/kg orally for 4 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no HDMP treatment)
Number of subjects: 14
Study: 1532974

Group type: EXPERIMENTAL
Intervention: Single drug therapy for induction of remission
Number of subjects: 1563

Group type: COMPARATOR
Intervention: Single drug therapy for maintenance of remission
Number of subjects: 1563
Study: 3894396

Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31975536

Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio (WHR) increase by 10%
Number of subjects: 0
Study: 27664111

Group type: EXPERIMENTAL
Intervention: GLUC-NAS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CAF-NAS
Number of subjects: 10

Group type: COMPARATOR
Intervention: PLAC-NAS
Number of subjects: 10
Study: 25670541

Group type: EXPERIMENTAL
Intervention: C-HART (30 Gy/2 Gy daily followed by twice-daily 1.4 Gy to a total of 70.6 Gy with concurrent mitomycin C/5-FU)
Number of subjects: 384

Group type: COMPARATOR
Intervention: HART (16 Gy/2 Gy daily followed by twice-daily 1.4 Gy to a total dose of 77.6 Gy alone)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: C-HART
Number of subjects: 384

Group type: COMPARATOR
Intervention: HART
Number of subjects: 384
Study: 23189940

Group type: EXPERIMENTAL
Intervention: 200 iu onabotulinum toxin A
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 22077535

Group type: EXPERIMENTAL
Intervention: Self-report administration of the Post-Concussion Scale
Number of subjects: 117

Group type: COMPARATOR
Intervention: Interview administration of the Post-Concussion Scale
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Interviewer gender (female)
Number of subjects: 117
Study: 18754005

Group type: EXPERIMENTAL
Intervention: Delta 9-tetrahydrocannabinol (THC) inhalation
Number of subjects: 7
Study: 16283371

Group type: EXPERIMENTAL
Intervention: Wearing red-colored clothing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Wearing black-colored clothing
Number of subjects: 10
Study: 14695462

Group type: EXPERIMENTAL
Intervention: Warfarin (anticoagulation intensity with INR > or = 1.5)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Warfarin (INR 1.5-1.9)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Warfarin (INR > or = 2.0)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Patients with sinus rhythm (control group)
Number of subjects: 509
Study: 11255456

Group type: COMPARATOR
Intervention: Physical activity (compared with no exercise)
Number of subjects: 9008
Study: 9385884

Group type: EXPERIMENTAL
Intervention: 20 mg rt-PA intravenous bolus followed by 80 mg i.v. infusion over 60 min (regimen A)
Number of subjects: 334

Group type: COMPARATOR
Intervention: 2.25 10(6) IU of streptokinase/60 min (B)
Number of subjects: 334

Group type: COMPARATOR
Intervention: 70 mg rt-PA over 90 min (C)
Number of subjects: 334

Group type: COMPARATOR
Intervention: 100 mg rt-PA over 90 min (D)
Number of subjects: 334
Study: 8173365

Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 3582928

Group type: EXPERIMENTAL
Intervention: Maternal positioning exercise (raising of the pelvis, abduction of the thighs, relaxed abdominal breathing)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Uninfluenced spontaneous version
Number of subjects: 61
Study: 2338687

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0
Study: 30841711

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) use before TASTE results: 39.8%
Number of subjects: 55809

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) use after TASTE results
Number of subjects: 55809

Group type: COMPARATOR
Intervention: All-cause mortality and definite stent thrombosis at 30 days
Number of subjects: 55809
Study: 27776003

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continuous Moderate Intensity (CON)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both HIIT and CON
Number of subjects: 21
Study: 26582883

Group type: EXPERIMENTAL
Intervention: rHPIV‐1/84/del 170/942A vaccine
Number of subjects: 0
Study: 23732788

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of propofol by a university‐degreed anesthesia registered nurse based on BIS values (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual scheme of intravenous sedation with midazolam and fentanyl administered by the endoscopic team (Group 0)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patient memory during procedure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Satisfaction scores (self-assessed by patients and assessed by 2 gastroenterologists)
Number of subjects: 100
Study: 21345766

Group type: EXPERIMENTAL
Intervention: Aprotinin (Trasylol®)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Wound drainage
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Compression treatment alone
Number of subjects: 80
Study: 19298406

Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Targeted Cryoablation of the Prostate (TCAP)
Number of subjects: 127
Study: 16979998

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) prophylaxis (300 mg/d for patients >35 kg and 5 mg/kg/d for patients <35 kg) with Pyridoxine 50 mg/d for 1 year
Number of subjects: 480

Group type: COMPARATOR
Intervention: Non-INH group (control)
Number of subjects: 480
Study: 14663472

Group type: EXPERIMENTAL
Intervention: Selenium-vitamin E supplement for at least 6 months
Number of subjects: 106

Group type: COMPARATOR
Intervention: No selenium-vitamin E supplement
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: LGPIN
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: HGPIN
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Selenium-vitamin E supplements
Number of subjects: 106
Study: 11133619

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 19
Study: 9773927

Group type: EXPERIMENTAL
Intervention: Group 1: omeprazole 20 mg once daily for 2 weeks, amoxicillin 500 mg thrice daily, metronidazole 250 mg thrice daily, roxithromycin 150 mg twice daily for 1 week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group 2: same antibiotic treatment as group 1 for 1 week, plus omeprazole treatment for 2 weeks
Number of subjects: 90
Study: 8143059

Group type: EXPERIMENTAL
Intervention: Lysine-aspirin inhalation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 16
Study: 3146893

Group type: EXPERIMENTAL
Intervention: Demonstration dose of sublingual nitroglycerin administered during the office visit
Number of subjects: 44

Group type: COMPARATOR
Intervention: No demonstration dose (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Demonstration dose of sublingual nitroglycerin
Number of subjects: 44
Study: 30661481

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 204
Study: 26306760

Group type: EXPERIMENTAL
Intervention: Fully covered self-expandable metal stent (FCSEMS)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Plastic stents
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: FCSEMS, Plastic stents, and early surgery
Number of subjects: 155
Study: 24615134

Group type: EXPERIMENTAL
Intervention: Active case finding program
Number of subjects: 35000

Group type: COMPARATOR
Intervention: Routine passive case finding activities
Number of subjects: 35000
Study: 23076820

Group type: EXPERIMENTAL
Intervention: 30% processed samples of E. scandens, C. gladiata and C. ensiformis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raw samples at 15% and processed samples at 15% and 30%
Number of subjects: 0
Study: 20529387

Group type: EXPERIMENTAL
Intervention: Peripheral arterial disease evaluated using the ankle-arm index (values < 0.9)
Number of subjects: 3786

Group type: EXPERIMENTAL
Intervention: Risk factors for peripheral arterial disease
Number of subjects: 3786

Group type: EXPERIMENTAL
Intervention: Protective factors for peripheral arterial disease
Number of subjects: 3786
Study: 18424606

Group type: EXPERIMENTAL
Intervention: Top tertile of the French National Nutrition and Health Program score
Number of subjects: 4976

Group type: COMPARATOR
Intervention: Lowest tertile of the French National Nutrition and Health Program score
Number of subjects: 4976
Study: 17272944

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 182

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 182
Study: 12599045

Group type: EXPERIMENTAL
Intervention: Nevirapine (Nvp)
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Zidovudine and Lamivudine (Zdv/3TC)
Number of subjects: 1307
Study: 11315832

Group type: EXPERIMENTAL
Intervention: Individual counseling for type 2 diabetic patients
Number of subjects: 431

Group type: COMPARATOR
Intervention: Universal intervention (comprehensive evaluation with feedback)
Number of subjects: 431
Study: 9141941

Group type: EXPERIMENTAL
Intervention: 5 micrograms isoproterenol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5 micrograms saline
Number of subjects: 60
Study: 8191881

Group type: EXPERIMENTAL
Intervention: Phenytoin (PT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (volunteers)
Number of subjects: 43
Study: 2884229

Group type: EXPERIMENTAL
Intervention: Experimental treatment designed to achieve and maintain near-normal glucose levels (n = 18)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Standard treatment (n = 15)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Patients with stimulated C-peptide levels greater than 0.2 pmol/mL
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Adults with IDDM (n = 296)
Number of subjects: 610
Study: 31647147

Group type: EXPERIMENTAL
Intervention: EPA-enriched supplement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 62
Study: 30629822

Group type: EXPERIMENTAL
Intervention: Balloon sinus dilation (BSD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Guidewire-based BSD system
Number of subjects: 18

Group type: COMPARATOR
Intervention: Probe-based BSD system
Number of subjects: 18
Study: 28582848

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization combined with radiofrequency ablation (TACE + RFA)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 106
Study: 26443662

Group type: EXPERIMENTAL
Intervention: Serious Illness Care Program (multicomponent, structured communication intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serious Illness Care Program (intervention)
Number of subjects: 0
Study: 23703730

Group type: EXPERIMENTAL
Intervention: Web-based acceptance and commitment therapy (ACT) intervention (WebQuit.org)
Number of subjects: 222

Group type: COMPARATOR
Intervention: National Cancer Institute's Smokefree.gov (control)
Number of subjects: 222
Study: 21499934

Group type: EXPERIMENTAL
Intervention: Inhalation of 100% oxygen for 50 minutes (Oxy50)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation of 100% oxygen followed by a 30-minute period after inhalation (After)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Before inhalation of pure oxygen (Before)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhalation of air (Control group) for 20 minutes (Oxy20)
Number of subjects: 0
Study: 19459553

Group type: EXPERIMENTAL
Intervention: Bupivacaine (100 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ropivacaine (150 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupivacaine (500 mg) loaded microspheres
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (Bupivacaine, Ropivacaine, Saline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupivacaine and Ropivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupivacaine (100 mg) and Ropivacaine (150 mg)
Number of subjects: 30
Study: 17720070

Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 IOL
Number of subjects: 179

Group type: COMPARATOR
Intervention: AcrySof MA60AC IOL
Number of subjects: 179
Study: 15302718

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) methylprednisolone (160 mg single dose)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Oral methylprednisolone (8-day tapering of total 160 mg)
Number of subjects: 190
Study: 11451713

Group type: EXPERIMENTAL
Intervention: Dietary supplements, either alone or in combination with hormonal treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet therapy
Number of subjects: 0
Study: 9926058

Group type: EXPERIMENTAL
Intervention: Intensive community mental health service
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard community mental health service
Number of subjects: 131
Study: 8138252

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (5 MU/m2 three times a week for 2 months, then 3 MU/m2 three times a week for 4 or 10 months)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha 2b (10 MU three times a week for 2 months, then 5 MU three times a week for 4 months; random allocation to stop or continue for an additional 6 months)
Number of subjects: 361
Study: 2679039

Group type: EXPERIMENTAL
Intervention: CHIP
Number of subjects: 112

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 112
Study: 1117460

Group type: EXPERIMENTAL
Intervention: Combination of 5-fluorouracil (5-FU), methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 80
Study: 31099229

Group type: COMPARATOR
Intervention: Standard acupoint
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dynamic acupoint positioning
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham-acupuncture (penetrating skin)
Number of subjects: 12
Study: 26350918

Group type: EXPERIMENTAL
Intervention: Fat-modified enteral formula containing medium-chain triglycerides (MCT), carnitine, and taurine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard enteral formula
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Fat-modified enteral formula
Number of subjects: 144